Targeted Therapy: Dendrimer‐Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy (Adv. Therap. 2/2021)

Specific and robust targeting of pathogenic cells would represent a major advance in treatment eye diseases including diabetic retinopathy. In article number 2000181 Rangaramanujam M. Kannan, Elia J. Duh co-workers use the corticosteroid triamcinolone conjugated to surface PAMAM-dendrimers, which are tree-like branching polymeric nanoparticles. This dendrimer-triamcinolone conjugate selectively targets activated, amoeboid microglia diseased retina, reprogramming them quiescent ramified microglia, with resulting neuroprotective effects suppression pathologic retinal angiogenesis. Dendrimer-mediated drug delivery represents promising therapeutic strategy high potency low toxicity. Image credit: Sylvia Heredia